Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gynecologic 2Plasma cell 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Peritoneal Neoplasms 1Multiple Myeloma 1Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 302Carboplatin 155Nivolumab 154Cisplatin 139Cyclophosphamide 130Paclitaxel 127Magnetic Resonance Spectroscopy 98Specimen Handling 95Radiotherapy 90Gemcitabine 87Dexamethasone 83Biopsy 81Ipilimumab 78Docetaxel 75Doxorubicin 75Rituximab 69Etoposide 67atezolizumab 61durvalumab 60Lenalidomide 59Radiation 59Pemetrexed 58Taxes 57Bevacizumab 54Prednisone 54fludarabine 54olaparib 53Cytarabine 49Vincristine 49Fluorouracil 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Has results × Glucose × 1 year × Clear all
NCT03740165 2026-05-04

KEYLYNK-001

Merck Sharp & Dohme LLC

Phase 3 Completed
1,367 enrolled 29 charts
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

NCT05116189 2026-03-09

KEYNOTE-B96

Merck Sharp & Dohme LLC

Phase 3 Active not recruiting
643 enrolled 17 charts 1 FDA
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02253316 2025-11-10

Phase II Study of IRD (Ixazomib, Lenalidomide, Dexamethasone) Post Autologous Stem Cell Transplantation Followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma

Washington University School of Medicine

Phase 2 Active not recruiting
236 enrolled 13 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡